Clinical Trial

The Dosimetry, Safety and Diagnostic Efficacy of ⁶⁸Ga-FC516 in Healthy Subjects and Patients With Prostate Cancer

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 29, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
This goal of this study is to investigate the dosimetry, safety, biodistribution of ⁶⁸Ga-FC516. In this study, we will evaluate the safety, biodistribution and dosimetry of ⁶⁸Ga-FC516 in subjects and compared them with the results of ⁶⁸Ga-labeled prostate cancer-targeting tracer imaging to evaluate the dosimetric characteristics and diagnostic efficacy of ⁶⁸Ga-FC516.
Protocol Amendment History 3 changes
notable Enrollment reduced: 30 -> 10 participants 2026-04-30
minor Trial arms changed: 3 -> 2 2026-04-30
critical Recruitment opened 2026-04-18
Trial Details
NCT Number NCT07468708
Lead Sponsor FindCure Biosciences (ZhongShan) Co., Ltd.
Collaborators: First Affiliated Hospital of Jinan University
Conditions Healthy Adult, Prostate Cancer
Enrollment 10 participants
Start Date 2026-03-09
Primary Completion 2026-07 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-04-29